Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01295944 : Carboplatin and Bevacizumab for Recurrent Ependymoma
PhasePhase 2
AgesMin: 18 Years Max: 99 Years
Eligibility
- INCLUSION CRITERIA:

Histologically proven intra-cranial or spinal ependymoma or anaplastic ependymoma. There
must be pathologic or imaging confirmation of tumor progression or regrowth.

The patient must have at least 1 block of tissue or 15 unstained slides at a minimum
available for central pathology review and molecular profiling of the tissue sample.

All patients must sign an informed consent indicating that they are aware of the
investigational nature of this study. Patients must have signed an authorization for the
release of their protected health information.

Patients must be > 18 years old.

Patients must have a Karnofsky performance status of > 60.

Patients must have adequate bone marrow function (WBC > 3,000/microliter, ANC > 1,500/mm^3,
platelet count of > 100,000/mm^3, and hemoglobin > 10 gm/dl), adequate liver function (SGOT
[AST <92.5 Units/L] and bilirubin < 1.5 mg/dL), and adequate renal function (creatinine <
1.5 mg/dL and calculated creatinine clearance > 60 cc/min) before starting therapy.
Eligibility level for hemoglobin may be reached by transfusion.

Patients must have shown unequivocal radiographic evidence for tumor progression by MRI or
CT scan.

At the time of registration: Patients must have recovered from the toxic effects of prior
therapy: > 28 days from any investigational agent, >28 days from prior cytotoxic therapy,
>14 days from vincristine, >42 days from nitrosoureas, >21 days from procarbazine
administration, and >7 days for non-cytotoxic agents, e.g., interferon, tamoxifen,
thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count). Any questions
related to the definition of non-cytotoxic agents should be directed to the Principal
Investigator.

Patients having undergone recent resection of recurrent or progressive tumor will be
eligible as long as all of the following conditions apply:

They have recovered from the effects of surgery.

A minimum of 28 days have elapsed from the day of surgery to the day of registration Step
2.

For core or needle biopsy, a minimum of 7 days must have elapsed prior to registration Step
2.

Residual disease following resection of recurrent ependymoma is not mandated for
eligibility into the study. To best assess the extent of residual disease post-operatively,
a CT/ MRI should be done no later than 96 hours in the immediate post-operative period or
at least 4 weeks post-operatively, within 14 days prior to consent. If the within 96-hour
after surgery scan is more than 14 days before consent the scan needs to be repeated. If
the steroid dose is increased between the date of imaging and consent, a new baseline
MRI/CT is required on a stable steroid dosage for at least 5 days.

Patients must have failed prior radiation therapy* and must have an interval of greater
than or equal to 42 days from the completion of radiation therapy to study entry. Note:
Patients with an indication for craniospinal radiotherapy (i.e., extensive leptomeningeal
disease) but have refused palliative craniospinal radiotherapy are eligible.

Patients with prior therapy that included interstitial brachytherapy or stereotactic
radiosurgery must have confirmation of true progressive disease rather than radiation
necrosis based upon either PET or Thallium scanning, MR spectroscopy, or
surgical/pathological documentation of disease.

Women of childbearing potential must have a negative B-HCG pregnancy test documented within
14 days prior to registration.

Women of childbearing potential and male participants agree to practice adequate

contraception.

EXCLUSION CRITERIA:

Patients must not have any significant medical illnesses that in the investigator s opinion
cannot be adequately controlled with appropriate therapy or would compromise the patient s
ability to tolerate this therapy.

Patients with a history of any other cancer (except non-melanoma skin cancer or carcinoma
insitu of the cervix), unless in complete remission and off of all therapy for that disease
for a minimum of 3 years are ineligible.

Patients must not have active infection or serious intercurrent medical illness.

Patients must not be pregnant/breast feeding. Patients must not be pregnant because animal
studies show that carboplatin and bevacizumab are teratogenic

Patients must not have any disease that will obscure toxicity or dangerously alter drug

metabolism.

Patients must not have received prior therapy with bevacizumab, or related drugs (previous
therapy with carboplatin is allowed).

Inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg and/or
diastolic blood pressure > 100 mmHg) despite antihypertensive medication.

New York Heart Association (NYHA) Grade II or greater congestive heart failure.

9 History of myocardial infarction or unstable angina within 12 months prior to Day 1.

History of stroke or transient ischemic attack.

Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent
peripheral arterial thrombosis) within 6 months prior to Day 1.

History of hemoptysis (greater than or equal to 1/2 teaspoon of bright red blood per
episode) within 1 month prior to Day 1.

Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic
anticoagulation). (To be eligible, Prothrombin time/international normalized ratio (PT INR)
should be < 1.4 for patients not on warfarin.)

Patients on full-dose anticoagulants (e.g., warfarin or LMW heparin) must meet both of the
following criteria to be eligible:

No active bleeding or pathological condition that carries a high risk of bleeding (e.g.,
tumor involving major vessels or known varices).

In-range INR (usually between 2 and 3) on a stable dose of oral anticoagulant or on a
stable dose of low molecular weight heparin.

Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior
to Day 1 of treatment or anticipation of need for major surgical procedure during the
course of the study.

Core biopsy or other minor surgical procedure, excluding placement of a vascular access
device, within 7 days prior to Day 1.

History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day
1.

Serious, non-healing wound, active ulcer, or untreated bone fracture.

Proteinuria as demonstrated by a UPC ratio greater than or equal to 1.0 at screening, or
Urine dipstick for proteinuria greater than or equal to 2+ (patients discovered to have
greater than or equal to 2+ proteinuria on dipstick urinalysis at baseline should undergo a
24 hour urine collection and must demonstrate less than or equal to 1g of protein in 24
hours to be eligible).

Known hypersensitivity to any component of bevacizumab.

Patients must not have current active hepatic or biliary disease (with exception of
patients with Gilbert s syndrome, asymptomatic gallstones, or stable chronic liver disease
per investigator assessment).
LinksPermanent Link to THIS page: http://virtualtrials.com/nct/display1trial.cfm?nct=NCT01295944      |      Link to official Clinicaltrials.gov listing
Locations
Bethesda, Maryland
Facility: National Institutes of Health Clinical Center, 9000 Rockville Pike
Investigator:
Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office Phone: 888-624-1937
Email not avaialable

Boston, Massachusetts
Facility: Harvard Cancer Center
Investigator:
Contact:
Email not avaialable

New York, New York
Facility: Memorial Sloan Kettering Cancer Center
Investigator:
Contact:
Email not avaialable

Houston, Texas
Facility: MD Anderson Cancer Center
Investigator:
Contact:
Email not avaialable




Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites